Drugs / CP1-1189
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002209 | — | AIDS dementia complex, HIV infectious disease | Centaur Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00002414 | — | HIV infectious disease | Centaur Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP1-1189 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297369 ↗ |
| Known as | CPI-1189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002209 ↗ |
| Known as | LU 02-584 | “Multiple Ascending Dose Pharmacokinetics of CPI-1189 (LU 02-584) in Fasted, HIV Infected, Male Volunteers on Combined Reverse Transcriptase and Protease Inhibitor Therapy” NCT00002209 ↗ |
| Modality | Small molecule | — CHEMBL4297369 ↗ |
| Route | Oral | “multiple-dose CPI-1189 or placebo by mouth” NCT00002209 ↗ |